Developing the next generation of monoclonal antibodies for the treatment of rheumatoid arthritis

British Journal of Pharmacology

Volumn 162, Issue 7, 2011, Pages 1470-1484

  Campbell, Jamie ^a   Lowe, David ^b   Sleeman, Matthew A ^a  

^a MEDIMMUNE   (United States)

^b MEDIMMUNE LTD   (United Kingdom)

Author keywords

antibody; biologics; cytokine; engineering; pattern recognition; phage display; rheumatoid arthritis; toll like receptors; transgenic mice

Indexed keywords

ABATACEPT; ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; HLA DR1 ANTIGEN; INFLIXIMAB; MONOCLONAL ANTIBODY; OFATUMUMAB; RITUXIMAB; TOCILIZUMAB; TRU 015; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANTIBODY STRUCTURE; ANTIGEN BINDING; AUTOIMMUNITY; B LYMPHOCYTE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; GENE FREQUENCY; GENETIC ASSOCIATION; GLYCOSYLATION; HUMAN; IMMUNOGENICITY; INNATE IMMUNITY; MOLECULAR BIOLOGY; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN MODIFICATION; REVIEW; RHEUMATOID ARTHRITIS;

ANIMALS; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; AUTOIMMUNITY; HUMANS; PROTEIN ENGINEERING; RECEPTORS, PATTERN RECOGNITION;

EID: 79952377840     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.01183.x     Document Type: Review

References (128)

1. Abdollahi-Roodsaz S, Joosten LA, Roelofs MF, Radstake TR, Matera G, Popa C, et al. (2007). Inhibition of Toll-like receptor 4 breaks the inflammatory loop in autoimmune destructive arthritis. Arthritis Rheum 56: 2957-2967. (Pubitemid 47502742)
2. Abdollahi-Roodsaz S, Joosten LA, Helsen MM, Walgreen B, van Lent PL, van den Bersselaar LA, et al. (2008a). Shift from toll-like receptor 2 (TLR-2) toward TLR-4 dependency in the erosive stage of chronic streptococcal cell wall arthritis coincident with TLR-4-mediated interleukin-17 production. Arthritis Rheum 58: 3753-3764.
3. Abdollahi-Roodsaz S, Joosten LA, Koenders MI, Devesa I, Roelofs MF, Radstake TR, et al. (2008b). Stimulation of TLR2 and TLR4 differentially skews the balance of T cells in a mouse model of arthritis. J Clin Invest 118: 205-216.
4. Abdollahi-Roodsaz S, Joosten LA, Koenders MI, van den Brand BT, van de Loo FA, van den Berg WB, (2009). Local interleukin-1-driven joint pathology is dependent on toll-like receptor 4 activation. Am J Pathol 175: 2004-2013.
5. Agoram B, (2009). Use of pharmacodynamic/pharmacokinetic modelling for starting dose selection in first-in-human trials of high-risk biologics. Br J Clin Pharmacol 67: 153-160.
6. Akashi S, Shimazu R, Ogata H, Nagai Y, Takeda K, Kimoto M, et al. (2000). Cutting edge: cell surface expression and lipopolysaccharide signaling via the toll-like receptor 4-MD-2 complex on mouse peritoneal macrophages. J Immunol 164: 3471-3475. (Pubitemid 30169795)
7. Alt FW, Blackwell TF, Yancopoulos GD, (1985). Immunoglobulin genes in transgenic mice. Trends Genet 1: 231-236.
8. Andersson U, Harris HE, (2010). The role of HMGB1 in the pathogenesis of rheumatic disease. Biochim Biophys Acta 1799: 141-148.
9. Bauer S, Müller T, Hamm S, (2009). Pattern recognition by Toll-like receptors. Adv Exp Med Biol 653: 15-34.
10. Boder ET, Midelfort KS, Wittrup KD, (2000). Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity. Proc Natl Acad Sci USA 97: 10701-10705.
11. Boulianne GL, Hozumi N, Shulman MJ, (1984). Production of functional chimaeric mouse/human antibody. Nature 312: 643-646. (Pubitemid 15218335)
12. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. (2006). The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54: 26-37. (Pubitemid 43122183)
13. Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M, (1989). Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 2: 244-247. (Pubitemid 19180612)
14. Buchan G, Barrett K, Turner M, Chantry D, Maini RN, Feldmann M, (1988). Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1 alpha. Clin Exp Immunol 73: 449-455.
15. Cambridge G, Stohl W, Leandro MJ, Migone TS, Hilbert DM, Edwards JC, (2006). Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum 54: 723-732.
16. Carter PJ, (2006). Potent antibody therapeutics by design. Nat Rev Immunol 6: 343-357.
17. Cecil RL, Nicholls EE, (1931). The Etiology of rheumatoid arthritis. Am J Med Sci 181: 12-24.
18. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. (2006). Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. REFLEX Trial Group. Arthritis Rheum 54: 2793-2806. (Pubitemid 44497758)
19. Dall'Acqua WF, Kinere PA, Wu H, (2006). Properties of Human IgG1s engineered for enhanced binding to the neontal Fc receptor (FcRn). J Biol Chem 281: 23514-23524. (Pubitemid 44274126)
20. Daubeuf B, Mathison J, Spiller S, Hugues S, Herren S, Ferlin W, et al. (2007). TLR4/MD-2 monoclonal antibody therapy affords protection in experimental models of septic shock. J Immunol 179: 6107-6114.
21. Deleuran BW, Chu CQ, Field M, Brennan FM, Katsikis P, Feldmann M, et al. (1992). Localization of interleukin-1 alpha, type 1 interleukin-1 receptor and interleukin-1 receptor antagonist in the synovial membrane and cartilage/pannus junction in rheumatoid arthritis. Br J Rheumatol 31: 801-809.
22. Dimasi N, Gao C, Fleming R, Woods RM, Yao XT, Shirinian L, et al. (2009). The design and characteriszation of oligospecific antibodies for simultaneous targeting of multiple disease mediators. J Mol Biol 393: 672-692.
23. Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A, B S R B R Control Centre Consortium, Symmons DP; BSR Biologics Register (2010). Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 69: 522-528. Epub 2009 Oct 22.
24. Drews J, (2004). Paul Ehrlich: Magister Mundi. Nat Rev Drug Discov 3: 797-801. (Pubitemid 39242831)
25. Drexler SK, Foxwell BM, (2010). The role of toll-like receptors in chronic inflammation. Int J Biochem Cell Biol 42: 506-518.
26. Dufner P, Jermutus L, Minter RR, (2006). Harnessing phage and ribsosome display for antibody optimisation. Trends Biotechnol 24: 523-529. (Pubitemid 44537457)
27. Dunn-Siegrist I, Leger O, Daubeuf B, Poitevin Y, Dépis F, Herren S, et al. (2007). Pivotal involvement of Fcgamma receptor IIA in the neutralization of lipopolysaccharide signaling via a potent novel anti-TLR4 monoclonal antibody 15C1. J Biol Chem 282: 34817-34827. (Pubitemid 350232459)
28. Edwards JC, Cambridge G, (1998). Rheumatoid arthritis: the predictable effect of small immune complexes in which antibody is also antigen. Br J Rheumatol 37: 126-130. Review.
29. Edwards JC, Cambridge G, (2001). Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 40: 205-211.
30. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. (2004). Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350: 2572-2581. (Pubitemid 38758544)
31. Edwards JC, Cambridge G, Leandro MJ, (2006). B cell depletion therapy in rheumatic disease. Best Pract Res Clin Rheumatol 20: 915-928. (Pubitemid 44382384)
32. Elliot MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katasikis P, et al. (1993). Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 36: 1681-1690. (Pubitemid 23360007)
33. Erridge C, (2010). Endogenous ligands of TLR2 and TLR4: agonists or assistants? J Leukoc Biol 87: 989-999.
34. Feldmann M, Brennan FM, Chantry D, Haworth C, Turner M, Abney E, et al. (1990). Cytokine production in the rheumatoid joint: implications for treatment. Ann Rheum Dis 49 (Suppl. 1): 480-486. (Pubitemid 20254614)
35. Feldmann M, Brennan FM, Maini RN, (1996). Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 14: 397-440. (Pubitemid 26130190)
36. Finckh A, Simard JF, Gabay C, Guerne PA, SCQM Physicians (2006). Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. Ann Rheum Dis 65: 746-752. (Pubitemid 43799173)
37. Frasnelli ME, Tarussio D, Chobaz-Péclat V, Busso N, So A, (2005). TLR2 modulates inflammation in zymosan-induced arthritis in mice. Arthritis Res Ther 7: R370-R379.
38. Genovese MC, Cohen S, Moreland L, Lium D, Robbins S, Newmark R, et al. (2004). Combination therapy with etanercept and analinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 50: 1412-1419. (Pubitemid 38608062)
39. Gerhardt S, Abbott WM, Hargreaves D, Pauptit RA, Davies RA, Needham MR, et al. (2009). Structure of IL-17A in complex with a potent fully human neutralizing antibody. J Mol Biol 394: 905-921.
40. Ghetie V, Ward ES, (2000). Multiple roles for the major histocompatibility complex class I-related receptor FcRn. Annu Rev Immunol 18: 739-766. (Pubitemid 30365396)
41. Gibson A, (1928). The etiology of rheumatoid arthritis. J Bone Joint Surg Am 10: 747-756.
42. Goh FG, Piccinini AM, Krausgruber T, Udalova IA, Midwood KS, (2010). Transcriptional regulation of the endogenous danger signal tenascin-C: a novel autocrine loop in inflammation. J Immunol 184: 2655-2662.
43. Green LL, Hardy MC, Maynard-Currie CE, Tsuda H, Louie DM, Mendez MJ, et al. (1994). Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. Nat Genet 7: 13-21. (Pubitemid 24232374)
44. Hale G, Dyer MJ, Clark MR, Phillips JM, Marcus R, Riechman L, et al. (1988). Remission induction in non-hodgkins lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet 2: 1394-1396.
45. Hawkins RE, Russell SJ, Winter G, (1992). Selection of phage antibodies by binding affinity. Mimicking affinity maturation. J Mol Biol 226: 889-896.
46. van der Heijden IM, Wilbrink B, Tchetverikov I, Schrijver IA, Schouls LM, Hazenberg MP, et al. (2000). Presence of bacterial DNA and bacterial peptidoglycans in joints of patients with rheumatoid arthritis and other arthritides. Arthritis Rheum 43: 593-598. (Pubitemid 30394951)
47. van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Toes RE, Huizinga TW, (2005). Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther 7: R949-R958.
48. Herzog C, Walker C, Pichler W, Aeschlimann A, Wassmer P, Stockinger H, et al. (1987). Monoclonal anti-CD4 in arthritis. Lancet 2: 1461-1462. (Pubitemid 18010343)
49. Hill JA, Southwood S, Sette A, Jevnikar AM, Bell DA, Cairns E, (2003). Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J Immunol 15: 538-541. (Pubitemid 36871358)
50. Horneff G, Krause A, Emmrich F, Kalden JR, Burmester GR, (1991a). Elevated levels of circulating tumor necrosis factor-alpha, interferon-gamma, and interleukin-2 in systemic reactions induced by anti-CD4 therapy in patients with rheumatoid arthritis. Cytokine 3: 266-267.
51. Horneff G, Winkler T, Kalden JR, Emmrich F, Burmester GR, (1991b). Human anti-mouse antibody response induced by anti-CD4 monoclonal antibody therapy in patients with rheumatoid arthritis. Clin Immunol Immunopathol 59: 89-103.
52. Huang Q, Ma Y, Adebayo A, Pope RM, (2007). Increased macrophage activation mediated through toll-like receptors in rheumatoid arthritis. Arthritis Rheum 56: 2192-2201. (Pubitemid 47173566)
53. Huang QQ, Pope RM, (2009). The role of toll-like receptors in rheumatoid arthritis. Curr Rheumatol Rep 11: 357-364.
54. Huizinga TW, Amos CI, van der Helm-van Mil AH, Chen W, van Gaalen FA, Jawaheer D, et al. (2005). Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis Rheum 52: 3433-3438. (Pubitemid 41612209)
55. Hyrich KL, Watson KD, Isenberg DA, Symmons DP, BSR Biologics Register (2008). The British Society for Rheumatology Biologics Register: 6 years on. Rheumatology (Oxford) 47: 1441-1443. Epub 2008 Jul 1.
56. Iwahashi M, Yamamura M, Aita T, Okamoto A, Ueno A, Ogawa N, et al. (2004). Expression of Toll-like receptor 2 on CD16+ blood monocytes and synovial tissue macrophages in rheumatoid arthritis. Arthritis Rheum 50: 1457-1467. (Pubitemid 38608067)
57. Iwasaki A, Medzhitov R, (2004). Toll-like receptor control of the adaptive immune responses. Nat Immunol 10: 987-995. (Pubitemid 41057715)
58. Jakobovits A, Amado RG, Yang X, Roskos L, Schwab G, (2007). From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice. Nat Biotechnol 25: 1134-1143. (Pubitemid 47542248)
59. Janeway CA Jr, Medzhitov R, (2002). Innate immune recognition. Annu Rev Immunol 20: 197-216. (Pubitemid 34293424)
60. Jones PT, Dear PH, Foote J, Neuberger MS, Winter G, (1986). Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321: 522-525. (Pubitemid 16052256)
61. Joosten LA, Koenders MI, Smeets RL, Heuvelmans-Jacobs M, Helsen MM, Takeda K, et al. (2003). Toll-like receptor 2 pathway drives streptococcal cell wall-induced joint inflammation: critical role of myeloid differentiation factor 88. J Immunol 171: 6145-6153. (Pubitemid 37467237)
62. Kim HM, Park BS, Kim JI, Kim SE, Lee J, Oh SC, et al. (2007). Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell 130: 906-917. (Pubitemid 47332573)
63. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al., TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) Study Investigators (2004). Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 28: 675-681. (Pubitemid 38296553)
64. Knight DM, Wagner C, Jordan R, McAleer MF, DeRita R, Fass DN, et al. (1995). The immunogenicity of the 7E3 murine monoclonal Fab antibody fragment variable region is dramatically reduced in humans by substitution of human for murine constant regions. Mol Immunol 32: 1271-1281. (Pubitemid 26015106)
65. Kobelt G, Woronoff AS, Richard B, Peeters P, Sany J, (2008). Disease status, costs and quality of life of patients with rheumatoid arthritis in France: the ECO-PR Study. Joint Bone Spine 75: 408-415.
66. Kohler G, Milstein C, (1975). Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495-497.
67. Lajas C, Abasolo L, Bellajdel B, Hernández-García C, Carmona L, Vargas E, et al. (2003). Costs and predictors of costs in rheumatoid arthritis: a prevalence-based study. Arthritis Rheum 15: 64-70. (Pubitemid 36286131)
68. Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, et al. (2006). Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci USA 103: 4005-4010.
69. Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA, (2002). An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 46: 2673-2677. (Pubitemid 36118931)
70. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC, (2006). Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 54: 613-620. (Pubitemid 43228639)
71. Lemery SJ, Zhang J, Rothmann MD, Yang J, Earp J, Zhao H, et al. (2010). U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab. Clin Cancer Res 16: 4331-4338. Epub 2010 Jul 2.
72. Leombruno JP, Einarson TR, Keystone EC, (2009). The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 68: 1136-1145.
73. Lonberg N, Taylor LD, Harding FA, Trounstine M, Higgins KM, Schramm SR, et al. (1994). Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature 368: 856-859. (Pubitemid 24137750)
74. Lundkvist J, Kastäng F, Kobelt G, (2008). The burden of rheumatoid arthritis and access to treatment: health burden and costs. Eur J Health Econ 8 (Suppl. 2): S49-S60.
75. MacLennan IC, Loewi G, Harding B, (1970). The role of immunoglobulins in lymphocyte-mediated cell damage, in vitro. I. Comparison of the effects of target cell specific antibody and normal serum factors on cellular damage by immune and non-immune lymphocytes. Immunology 18: 397-404.
76. McCafferty J, Griffiths AD, Winter G, Chiswell DJ, (1990). Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348: 552-554. (Pubitemid 120015109)
77. McCormack WJ, Parker AE, O'Neill LA, (2009). Toll-like receptors and NOD-like receptors in rheumatic diseases. Arthritis Res Ther 11: 243-250.
78. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. (1999). Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354: 1932-1939.
79. Maravic M, (2010). Economic impact of rheumatoid arthritis (RA) biotherapies in France. Joint Bone Spine 77: 319-324.
80. Matzinger P, (1994). Tolerance, danger, and the extended family. Annu Rev Immunol 12: 991-1045. (Pubitemid 24140436)
81. Medzhitov R, Janeway CA Jr, (1997). Innate immunity: the virtues of a nonclonal system of recognition. Cell 91: 295-298. (Pubitemid 27467959)
82. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr, (1997). A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388: 394-397. (Pubitemid 27334820)
83. Meng G, Rutz M, Schiemann M, Metzger J, Grabiec A, Schwandner R, et al. (2004). Antagonistic antibody prevents toll-like receptor 2-driven lethal shock-like syndromes. J Clin Invest 113: 1473-1481. (Pubitemid 39071703)
84. Midwood K, Sacre S, Piccinini AM, Inglis J, Trebaul A, Chan E, et al. (2009). Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat Med 15: 774-780.
85. Miyake K, (2007). Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. Semin Immunol 19: 3-10. (Pubitemid 46498750)
86. Moisan J, Faggioni R, Liang M, Bowen MA, Schnieder AK, Lee RZW, et al. (2009). MEDI-5117: a human high afffinity anti-IL-6 monoclonal antibody with enhanced serum half life in development for the treatment of inflammation and rheumatological disorders. ACR/ARHP Scientific Meeting 09, Philadelphia, Presentation 401.
87. Morrison SL, Johnson MJ, Herzenberg LA, Oi VT, (1984). Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA 81: 6851-6855. (Pubitemid 15221019)
88. Neuberger MS, Williams GT, Mitchell EB, Jouhal SS, Flanagan JG, Rabbitts TH, (1985). A hapten-specific chimaeric IgE antibody with human physiological effector function. Nature 314: 268-270. (Pubitemid 15076516)
89. Nishimoto N, Kishimoto T, (2008). Humanized antihuman IL-6 receptor antibody, tocilizumab. Handb Exp Pharmacol 181: 151-160.
90. O'Neill LA, (2008). Primer: toll-like receptor signaling pathways-what do rheumatologists need to know? Nat Clin Pract Rheumatol 4: 319-327. (Pubitemid 351791443)
91. O'Neill LA, Bryant CE, Doyle SL, (2009). Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacol Rev 61: 177-197.
92. Ospelt C, Brentano F, Rengel Y, Stanczyk J, Kolling C, Tak PP, et al. (2008). Overexpression of toll-like receptors 3 and 4 in synovial tissue from patients with early rheumatoid arthritis: toll-like receptor expression in early and longstanding arthritis. Arthritis Rheum 58: 3684-3692.
93. Park BS, Song DH, Kim HM, Choi BS, Lee H, Lee JO, (2009). The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 458: 1191-1195.
94. Popa C, Leandro MJ, Cambridge G, Edwards JC, (2007). Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs. Rheumatology (Oxford) 46: 626-630. (Pubitemid 46523308)
95. Pugner KM, Scott DI, Holmes JW, Hieke K, (2000). The costs of rheumatoid arthritis: an international long-term view. Semin Arthritis Rheum 29: 305-320. (Pubitemid 30235982)
96. Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, et al. (2005). Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 52: 27-35. (Pubitemid 40129229)
97. Radstake TR, Roelofs MF, Jenniskens YM, Oppers-Walgreen B, van Riel PL, Barrera P, et al. (2004). Expression of toll-like receptors 2 and 4 in rheumatoid synovial tissue and regulation by proinflammatory cytokines interleukin-12 and interleukin-18 via interferon-gamma. Arthritis Rheum 50: 3856-3865. (Pubitemid 39643932)
98. Raghavan M, Bjorkman PJ, (1996). Fc receptors and their interactions with immunoglobulins. Annu Rev Cell Dev Biol 12: 181-220. (Pubitemid 26422713)
99. Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC, (2005). Monoclonal antibody successes in the clinic. Nat Biotechnol 23: 1073-1078. (Pubitemid 41486385)
100. Reynolds JM, Pappu BP, Peng J, Martinez GJ, Zhang Y, Chung Y, et al. (2010). Toll-like receptor 2 signaling in CD4(+) T lymphocytes promotes T helper 17 responses and regulates the pathogenesis of autoimmune disease. Immunity 32: 692-702.
101. Roopenian DC, AKilesh S, (2007). FcRn: the neonatal receptor comes of age. Nat Rev Immunol 7: 715-725. (Pubitemid 47327396)
102. Sacre SM, Andreakos E, Kiriakidis S, Amjadi P, Lundberg A, Giddins G, et al. (2007). The Toll-like receptor adaptor proteins MyD88 and Mal/TIRAP contribute to the inflammatory and destructive processes in a human model of rheumatoid arthritis. Am J Pathol 170: 518-525. (Pubitemid 47339389)
103. Schier R, McCall A, Adams GP, Marshall KW, Merritt H, Yim M, et al. (1996). Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J Mol Biol 263: 551-567. (Pubitemid 26382075)
104. Schumacher HR Jr, Arayssi T, Crane M, Lee J, Gerard H, Hudson AP, et al. (1999). Chlamydia trachomatis nucleic acids can be found in the synovium of some asymptomatic subjects. Arthritis Rheum 42: 1281-1284. (Pubitemid 29268967)
105. Seibl R, Birchler T, Loeliger S, Hossle JP, Gay RE, Saurenmann T, et al. (2003). Expression and regulation of Toll-like receptor 2 in rheumatoid arthritis synovium. Am J Pathol 162: 1221-1227. (Pubitemid 36350666)
106. Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, et al. (2003). The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccaharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 278: 3466-3473. (Pubitemid 36801263)
107. Smolen JS, Kay J, Doyle MK, Landewé R, Matteson EL, Wollenhaupt J, et al., GO-AFTER Study Investigators (2009). Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 374: 210-221.
108. Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. (2010). EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69: 964-975.
109. Steidl S, Ratsch O, Brocks B, Durr M, Thomassen-Wolf E, (2008). In vitro affinity maturation of human GM-CSF antibodies by targeted CDR-diversification. Mol Immunol 46: 135-144.
110. Stemmer WP, (1994). DNA shuffling by random fragmentation and reassembly: in vitro recombination for molecular evolution. Proc Natl Acad Sci USA 91: 10747-10751. (Pubitemid 24329076)
111. Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, et al. (2009). Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 18: 737-744.
112. Symmons DP, (2002). Epidemiology of rheumatoid arthritis: determinanats of onset, persistence and outcome. Best Pract Res Clin Rheumatol 16: 707-722.
113. Symmons DP, Silman AJ, (2004). Anti-tumor necrosis factor alpha therapy and the risk of lymphoma in rheumatoid arthritis: no clear answer. Arthritis Rheum 50: 1703-1706. (Pubitemid 38725080)
114. Tan JY, Li S, Yang K, Ma B, Chen W, Zha C, et al. (2010). Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: a meta-analysis. J Dermatolog Treat 5: 1-14.
115. Taylor LD, Carmack CE, Schramm SR, Mashayekh R, Higgins KM, Kuo CC, et al. (1992). A transgenic mouse that expresses a diversity of human sequence heavy and light chain immunoglobulins. Nucleic Acids Res 20: 6287-6295. (Pubitemid 23039159)
116. Taylor LD, Carmack CE, Huszar D, Higgins KM, Mashayekh R, Sequar G, et al. (1994). Human immunoglobulin transgenes undergo rearrangement, somatic mutation and class switching in mice that lack endogenous IgM. Int Immunol 6: 579-591. (Pubitemid 24111609)
117. Ternant D, Paintaud G, (2005). Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins. Expert Opin Biol Ther Suppl. 1: S37-S47. (Pubitemid 41243344)
118. Thorbecke GJ, Shah R, Leu CH, Kuruvilla AP, Hardison AM, Palladino MA, (1992). Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice. Proc Natl Acad Sci USA 89: 7375-7379.
119. Tidswell M, Tillis W, Larosa SP, Lynn M, Wittek AE, Kao R, et al., Eritoran Sepsis Study Group (2010). Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis. Crit Care Med 38: 72-83.
120. Tsan MF, Gao B, (2007). Pathogen-associated molecular pattern contamination as putative endogenous ligands of Toll-like receptors. J Endotoxin Res 13: 6-14. (Pubitemid 47471330)
121. Vanags D, Williams B, Johnson B, Hall S, Nash P, Taylor A, et al. (2006). Therapeutic efficacy and safety of chaperonin 10 in patients with rheumatoid arthritis: a double-blind randomised trial. Lancet 368: 855-863. (Pubitemid 44292809)
122. Verhoeyen M, Riechmann L, (1988). Engineering of antibodies. Bioessays 8: 74-78.
123. Weir AN, Nesbitt A, Chapman AP, Popplewell AG, Antoniw P, Lawson AD, (2002). Formatting antibody fragments to mediate specific therapeutic functions. Biochem Soc Trans 30: 512-516. (Pubitemid 35001587)
124. Wendling D, Racadot E, Wijdenes J, (1993). Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J Rheumatol 20: 259-262. (Pubitemid 23066035)
125. Williams RO, Feldmann M, Maini RN, (1992). Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 89: 9784-9788.
126. Wu C, Ying HL, Grineell C, Bryant S, Miller R, Clabbers A, et al. (2007). Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol 25: 1290-1297. (Pubitemid 350076510)
127. Yeung YA, Leabman MK, Marvin JS, Qiu J, Adams CW, Lien S, et al. (2009). Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates. J Immunol 182: 7663-7671.
128. Zalevsky J, Chamberlain AK, Horton HM, KArki S, Leung IW, Sproule TJ, et al. (2010). Enhanced antibody half-life improves in vivo activity. Nat Biotechnol 28: 157-159.